Natalizumab (Tysabri).
Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
Selewski
D T
DT
Department of Pediatrics, Division of Pediatric Nephrology, University of Michigan, C.S. Mott Children's Hospital, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-7789, USA. dselewsk@med.umich.edu
Shah
G V
GV
Segal
B M
BM
Rajdev
P A
PA
Mukherji
S K
SK
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized; D001921:Brain / Q000187:drug effects / Q000276:immunology*; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology; D002464:Cell Migration Inhibition / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology*; D018448:Models, Immunological; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab